NCT06566898 Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients
| NCT ID | NCT06566898 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai General Hospital, China |
| Condition | Pneumonia |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2026-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2024-08-01 with a primary completion date of 2026-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions: 1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ? 2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ? 3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?
Eligibility Criteria
Inclusion Criteria: * Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011. * Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination. Exclusion Criteria: * Patients whose biological samples may be contaminated; * Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.
Contact & Investigator
Mei Kang, MPH
PRINCIPAL INVESTIGATOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Frequently Asked Questions
Who can join the NCT06566898 clinical trial?
This trial is open to participants of all sexes, studying Pneumonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06566898 currently recruiting?
Yes, NCT06566898 is actively recruiting participants. Contact the research team at mei.kang@shgh.cn for enrollment information.
Where is the NCT06566898 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06566898 clinical trial?
NCT06566898 is sponsored by Shanghai General Hospital, China. The principal investigator is Mei Kang, MPH at Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. The trial plans to enroll 800 participants.